BIOTRICITY INC. (BTCY): Nasdaq/NYSE listing notice — Biotricity receives Nasdaq delisting determination for failure to meet MVLS requirement; intends to appeal

BIOTRICITY INC.

Received delisting letter on Jan 30, 2024, for not regaining compliance with $35M MVLS requirement by Jan 29, 2024.
Trading suspension on Nasdaq Capital Market set for Feb 8, 2024, unless the company appeals.
Company plans to request a hearing before the Nasdaq Hearings Panel to appeal and present a compliance plan.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BIOTRICITY INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

January 30, 2024, the Company received a delisting determination letter (the “Letter”) from the Staff advising the Company that the Staff had determined that the Company did not regain compliance with the MVLS Requirement by the Compliance Date because the Company’s MVLS did not close at or above $35 million for a minimum of 10 consecutive business days prior to the Compliance Date. As a result, unless the Company requests an appeal of the Staff’s determination, trading of the Company’s common stock on the Nasdaq Capital Market will be suspended at the opening of business on February 8, 2024

View on SEC.gov

88 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIOTRICITY INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-004806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.